Why BGPT?
logo

Assess an author's data and outputs

See the raw experimental evidence behind an author's publications and reproducibility signals.







Press Enter ↵ to solve



    Fuel Your Discoveries




     Quick Explanation


    Takeya Kasukawa — scientific strength snapshot
    Based on the provided record, Kasukawa’s most concrete scientific signal is a recent, multi-omics study of alternative transcription start sites (TSSs) and proteoform expansion in human myeloid differentiation/activation: Author Review (BGPT). The excerpt reports very large discovery-scale output (21,219 transcripts; 9,277 genes) plus proteogenomics workflows and explicit falsifiability criteria, but there are still blind spots noted in the dataset (e.g., single iPSC line dependence; in vitro/in vivo extrapolation limits).



     Long Explanation


    Author Review: Takeya Kasukawa
    Scope: This review is constrained to the information explicitly provided to me (not external web lookups), especially the single detailed study excerpt supplied.
    Visuals first (raw excerpt numbers)
    Source for the numeric visuals
    The transcript/gene counts and the 46% breadth claim are taken directly from the provided excerpt of the study dated Feb 03, 2026.
    1) What the author’s provided record shows (biological focus)
    Primary biological theme
    • The provided study excerpt centers on how alternative promoter/TSS usage changes the gene products available for innate immune programs during myeloid differentiation and monocyte activation, with an emphasis on expanding isoform/proteoform diversity in macrophage-like contexts.
    • It explicitly ties transcriptional mechanisms (TSS/TXN isoform switching) to downstream proteogenomic outputs, including mass-spectrometry validation steps described in the excerpt.
    2) Scientific strength (evidence quality signals & skepticism)
    What looks strong in the provided excerpt
    • Discovery scale + annotation integration: the excerpt reports very large discovery output (tens of thousands of transcripts, mapping to thousands of genes) along with explicit handling of transcripts not in reference annotation (e.g., transcripts mapping outside the stated gene annotation set).
    • Multi-omic/orthogonal validation posture: the excerpt includes both transcript-level TSS discovery/isoform discovery and a proteogenomics/MS layer intended to validate translation of predicted ORFs/proteoforms.
    • Falsifiability explicitly described: the excerpt includes an explicit “how to falsify” framing (e.g., independent replication showing promoter usage does not alter ORF content/protein localization, or failures in MS validation/consistency of activation-induced TSS engagement).
    Critical limitations / blind spots called out in the excerpt
    • Model dependence: reliance on a single iPSC line (the excerpt explicitly mentions PB001.1) constrains generality across donor/genetic backgrounds.
    • Technical bias risk: the excerpt flags 5' bias and challenges in termination-site inference, which can affect which promoters/TSSs are called as “active.”
    • Proteoform validation ceiling: the excerpt notes partial validation constraints due to proteomic detectability and sequence similarity—i.e., even if proteoforms are predicted, MS coverage can miss them.
    • Annotation-dependence: using a specific reference annotation version (GENCODE v39) can both miss novel biology and shape interpretation of “uncharacterised” vs “annotated.”
    3) Evidence-based bioinformatics credibility checks (based only on excerpted methods)
    The above categories are drawn only from the method list inside the provided excerpt (e.g., CAGE, Cap-trap full-length cDNA sequencing/isoform discovery, proteogenomics/MS, and pathway/TF analyses).
    4) Scientific citation metrics available in the provided record (limited context)
    • Provided record shows h-index = 1, total citations = 3, paper count = 3.
    • An OpenAlex query attempt timed out, so I cannot verify broader citation landscape beyond the provided excerpt.
    Note: citation metrics are inherently noisy for early-career researchers and depend strongly on indexing coverage; use them only as weak context signals, not as proof of scientific merit.
    5) What would most likely disprove the central claims (from excerpt)
    These criteria are explicitly described in the excerpt’s “how_to_falsify.”
    Bottom-line scientific critique (confidence-bounded)
    • Confidence: moderate (limited to one detailed excerpt). The record suggests strong competence in transcriptome-to-proteogenome reasoning and in producing large-scale promoter/TSS discovery linked to functional innate-immune programming hypotheses.
    • Key fragility points are also clearly present in the excerpt: single iPSC line dependence, 5' bias/termination uncertainty, and proteomic detectability limits—all of which can inflate discovery while under-measuring functional protein consequences unless independently replicated and broadened across donors/models.
    What would change my assessment: additional provided study excerpts (or the full paper) showing cross-donor replication, stronger protein-level validation coverage, and in vivo-compatible functional assays for the specific novel proteoforms implied by the TSS/isoform switching.


    Feedback:    

    Updated: March 22, 2026

     Analysis Wizard



    It will extract the provided excerpt’s key counts and fractions, then generate updated, reproducible Plotly-ready summary arrays for comparative visualization of discovery scale and breadth claims.



     Hypothesis Graveyard


    The claim that innate immune plasticity is driven mainly by static gene repertoires rather than isoform/promoter diversity is weaker if promoter/TSS engagement systematically changes isoform/proteoform repertoires across differentiation and activation (as the excerpt argues).

     Science Art


    Author Review: Takeya Kasukawa Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion








    Get Ahead With Science Insights

    Custom summaries of the latest cutting edge Science research. Every Friday. No Ads.


    My BGPT






     Trending